Only one topical therapy exists; most patients remain inadequately treated
In a January partnership valued at up to half a billion dollars, Royalty Pharma and Teva have placed a significant wager on TEV-408, an experimental antibody that targets the immune pathway underlying vitiligo — a condition that, despite affecting millions worldwide, has long existed at the margins of medical attention. The deal reflects a broader reckoning with diseases that are too often dismissed as cosmetic yet carry profound psychological weight for those who live with them. With FDA Fast Track status already granted and Phase 2b trials on the horizon, the collaboration marks a rare moment when financial ambition and genuine unmet human need appear to be moving in the same direction.
- Millions of vitiligo patients worldwide have had access to only a single topical treatment covering a fraction of the body, leaving most without meaningful medical recourse as white patches spread and psychological suffering deepens.
- TEV-408, a monoclonal antibody designed to block the IL-15 immune protein responsible for attacking pigment-producing cells, has already earned FDA Fast Track designation — signaling that regulators recognize the urgency of finding a systemic solution.
- Royalty Pharma's $75 million upfront commitment launches a Phase 2b trial in 2026, with an additional $425 million contingent on results that prove the drug can safely and effectively intervene in the disease's progression.
- The funding structure binds both companies to the science: Royalty Pharma earns nothing unless TEV-408 reaches the market, creating a rare alignment of commercial incentive and patient outcome.
- Trial results expected in 2026 will determine whether this partnership becomes a turning point for vitiligo patients — or another promising candidate that falls short before the finish line.
On a January morning, two pharmaceutical companies announced a partnership worth up to $500 million, staking their bet on a new approach to an old and underserved disease. Royalty Pharma, a New York firm that funds drug development in exchange for future royalties, committed the capital to accelerate Teva's work on TEV-408 — an experimental antibody designed to block interleukin-15, a protein central to the immune attack that strips pigment-producing cells from the skin in vitiligo patients.
Vitiligo is rarely understood for what it truly is. Affecting between 0.5 and 2 percent of the global population, it is not merely a cosmetic condition but a chronic autoimmune disease that carries an invisible burden of anxiety, depression, and social withdrawal. Yet medicine has offered these patients almost nothing: a single approved topical therapy, usable on only a small portion of the body's surface, leaving the majority of sufferers without adequate treatment.
TEV-408 represents a different kind of intervention — a precision antibody that aims to stop the immune system from destroying its own pigment cells. Early Phase 1b results were promising enough that the FDA granted the drug Fast Track designation in May 2025. The therapy is also being explored for celiac disease, another IL-15-driven autoimmune condition.
The financial structure is designed to keep both parties honest. Royalty Pharma provides $75 million immediately to fund a Phase 2b trial Teva plans to launch in 2026. A further $425 million becomes available only if those results are compelling enough to justify Phase 3 development. If the drug eventually reaches the market, Teva pays milestones and royalties — meaning Royalty Pharma profits only when patients do.
For Teva, the deal advances its broader shift toward innovative therapies. For the millions living with vitiligo — managing visible difference while carrying its unseen psychological weight — the prospect of a systemic treatment that addresses both dimensions is something their medical landscape has long lacked: a credible reason for hope.
Two pharmaceutical companies announced a half-billion-dollar partnership on a Saturday morning in January, betting that a new approach to an old skin disease might finally offer relief to millions of people who have had few options. Royalty Pharma, a New York-based firm that finances drug development in exchange for future royalties, committed up to $500 million to accelerate Teva's work on TEV-408, an experimental antibody designed to block a protein called interleukin-15, or IL-15. The drug is being tested for vitiligo, a chronic autoimmune condition that destroys the cells responsible for skin pigmentation, leaving white patches across the body.
Vitiligo sounds like a cosmetic problem, but it is far more than that. Between 0.5 and 2 percent of the global population has the disease—millions of people—yet many go undiagnosed. The condition can appear on anyone regardless of age, skin tone, or ethnicity. What makes vitiligo particularly cruel is not just the visible depigmentation, but the psychological weight it carries. Patients report anxiety, depression, and social isolation. They withdraw from public life. They avoid intimacy. The emotional toll can be as disabling as the physical one. Currently, only a single topical therapy is approved, and it can only be used on up to 10 percent of the body's surface. For most people with vitiligo, this means remaining inadequately treated, watching white patches spread, and living with the knowledge that medicine has little to offer them.
That is where TEV-408 enters the picture. The drug is a monoclonal antibody—a laboratory-engineered protein that acts like a precision weapon in the immune system. By blocking IL-15, which plays a central role in immune-mediated diseases, the antibody aims to stop the body from attacking its own pigment-producing cells. Early data from Phase 1b trials in vitiligo patients have shown enough promise that the U.S. Food and Drug Administration granted the drug Fast Track designation in May 2025, a designation reserved for therapies addressing serious unmet medical needs. TEV-408 is also being tested in a Phase 2a study for celiac disease, another autoimmune condition where IL-15 drives intestinal inflammation.
The funding structure reflects both companies' confidence and their caution. Royalty Pharma will immediately provide $75 million to fund a Phase 2b trial, which Teva plans to launch in 2026. If those results prove compelling, Royalty Pharma has the option to invest an additional $425 million to support Phase 3 trials—the final stage before seeking regulatory approval. If TEV-408 reaches the market, Teva will pay Royalty Pharma milestones and royalties on worldwide sales. This arrangement aligns the interests of both parties: Royalty Pharma profits only if the drug succeeds, so it has every reason to see the science move forward efficiently.
For Teva, the deal supports what the company calls its Pivot to Growth strategy, a shift away from generic drugs toward innovative therapies that command higher prices and offer greater returns. Richard Francis, Teva's president and chief executive, framed the partnership as essential to accelerating the pipeline and delivering solutions to patients with chronic autoimmune diseases. Pablo Legorreta, the chief executive of Royalty Pharma, emphasized the company's role as a long-term partner in funding transformative therapies, noting that vitiligo represents a significant unmet need despite its prevalence.
What happens next depends on the data. Teva has committed to sharing trial results during 2026. If Phase 2b shows that TEV-408 can safely and effectively restore pigmentation or halt its loss in a meaningful number of patients, the path to Phase 3 opens. If those final trials succeed, the drug could reach patients within a few years. For the millions of people living with vitiligo—managing the physical visibility of their disease while carrying its invisible psychological burden—the possibility of a systemic therapy that addresses both dimensions represents something that has been absent from their medical landscape: genuine hope.
Notable Quotes
Vitiligo is a chronic autoimmune skin disease that can have a profound emotional and psychosocial burden, yet current treatment options are insufficient.— Pablo Legorreta, CEO of Royalty Pharma
Vitiligo represents a significant unmet need, with only one approved topical treatment currently available and no systemic options.— Richard Francis, President and CEO of Teva
The Hearth Conversation Another angle on the story
Why does a skin disease that affects less than 2 percent of the population warrant half a billion dollars in funding?
Because the people living with it have almost nowhere to turn. One topical cream, usable on 10 percent of the body. That's the entire arsenal. When you're talking about a condition that causes depression and social isolation, the market failure becomes a human failure.
So this is about the emotional burden as much as the physical one?
Entirely. Vitiligo is visible. You can't hide it the way you might hide other autoimmune conditions. People withdraw. They avoid being seen. The disease becomes a prison of their own making because society makes them feel like they should hide. A systemic drug that works could change that calculus completely.
Why IL-15 specifically? What makes that protein a good target?
It's involved in multiple immune pathways, not just vitiligo. That's actually why this deal is interesting—they're testing it for celiac disease too. If blocking IL-15 works broadly, you're not just treating one disease. You're potentially opening a door to treating a whole class of autoimmune conditions.
What's the risk here? Why wouldn't this just work?
Phase 1b data is preliminary. It's promising, but it's early. You need Phase 2b to show it actually works in a larger group. Then Phase 3 to prove it's safe and effective enough for the FDA. Any of those could fail. The drug could work in the lab and fail in people. Or it could work but cause unexpected side effects.
If it does work, what changes?
For vitiligo patients, everything. They get a systemic option—something that works throughout the body, not just on small patches. They get their lives back. For Teva, it's a flagship drug for their new strategy. For Royalty Pharma, it's a bet that pays off handsomely if the science holds.
When will we know?
Teva said they'd share results in 2026. So we're waiting for Phase 1b data to be published, then watching Phase 2b unfold. If that looks good, the $425 million option gets exercised and Phase 3 begins. We're probably looking at 2028 or 2029 before anyone knows if this actually works.